In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog

Shuichi Tanabe, Yasuyuki Shimohigashi, Yasuhisa Nakayama, Takashi Makino, Tsugumi Fujita, Takeru Nose, Gozoh Tsujimoto, Teruo Yokokura, Mikihiko Naito, Takashi Tsuruo, Tetsuya Terasaki

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The blood-brain barrier (BBB) transport and metabolism of a novel arginine-vasopressin fragment 4-9 [AVP4-9, isoelectric point; (pl) = 9.2] analog, that is, cationic AVP4-9 (C-AVP4-9, PI = 9.8), were examined in vivo and in vitro. At 45 min after an i.v. administration to mice, the cerebrum-to-plasma concentration ratios of 35S-labeled AVP4-9 and 1251-labeled C-AVP4-9 were 0.103 and 0.330 ml/g cerebrum, respectively, and the BBB permeation clearances were 1.47 x 10-4 and 3.10 x 10-4 ml/min/g cerebrum, respectively. In the in vitro study using mouse brain capillary endothelial cells immortalized by SV40 infection (MBEC4), the acid- resistant binding values of 35S-labeled AMP4-9 and 125l-labeled C- AVP4-9 to MBEC4 at 120 min were 0.93 and 1.95 μl/mg protein (as the cell/medium ratios), respectively. 35S-labeled AVP4-9 showed two-phase saturable acid-resistant binding, and its half-saturation constants (K(D)) were 3.8 nM (high affinity) and 45.7 μM (low affinity). 125l-labeled C- AVP4-9 showed single-phase saturable acid-resistant binding, with a K(D) value of 16.4 μM. The acid-resistant binding of 125l-labeled C-AVP4-9 was significantly dependent on temperature and medium osmolarity. The acid- resistant binding of 1251-labeled C-AVP4-9 was inhibited by dancylcadaverine, phenylarsine oxide (endocytosis inhibitors), 2,4- dinitrophenol (a metabolic inhibitor), and AVP4-9, poly(L-lysine), and protamine (cationic substances), but not by poly(L-glutamic acid) (an anionic peptide) and the V1 and V2 vasopressin receptor antagonists. In addition, the conversion of C-AVP4-9 to AVP4-9 in the cerebral homogenate was confirmed by HPLC and mass spectrometry. The present results demonstrate that C-AVP4-9 is transported through the BBB more effectively than AVP4-9, via absorptive-mediated endocytosis, and that C-AVP4-9 is converted to the neuroactive parent peptide, AVP4-9, in the cerebrum.

Original languageEnglish
Pages (from-to)561-568
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume290
Issue number2
Publication statusPublished - Aug 1 1999

Fingerprint

Blood-Brain Barrier
Cerebrum
Acids
Endocytosis
2,4-Dinitrophenol
Peptides
Protamines
Isoelectric Point
Osmolar Concentration
Lysine
Mass Spectrometry
Endothelial Cells
High Pressure Liquid Chromatography
argipressin (4-9)
In Vitro Techniques
Temperature
Brain
Infection
Proteins

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog. / Tanabe, Shuichi; Shimohigashi, Yasuyuki; Nakayama, Yasuhisa; Makino, Takashi; Fujita, Tsugumi; Nose, Takeru; Tsujimoto, Gozoh; Yokokura, Teruo; Naito, Mikihiko; Tsuruo, Takashi; Terasaki, Tetsuya.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 290, No. 2, 01.08.1999, p. 561-568.

Research output: Contribution to journalArticle

Tanabe, S, Shimohigashi, Y, Nakayama, Y, Makino, T, Fujita, T, Nose, T, Tsujimoto, G, Yokokura, T, Naito, M, Tsuruo, T & Terasaki, T 1999, 'In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog', Journal of Pharmacology and Experimental Therapeutics, vol. 290, no. 2, pp. 561-568.
Tanabe, Shuichi ; Shimohigashi, Yasuyuki ; Nakayama, Yasuhisa ; Makino, Takashi ; Fujita, Tsugumi ; Nose, Takeru ; Tsujimoto, Gozoh ; Yokokura, Teruo ; Naito, Mikihiko ; Tsuruo, Takashi ; Terasaki, Tetsuya. / In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog. In: Journal of Pharmacology and Experimental Therapeutics. 1999 ; Vol. 290, No. 2. pp. 561-568.
@article{1445ec7f96834be19cb2bcdecea843bf,
title = "In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog",
abstract = "The blood-brain barrier (BBB) transport and metabolism of a novel arginine-vasopressin fragment 4-9 [AVP4-9, isoelectric point; (pl) = 9.2] analog, that is, cationic AVP4-9 (C-AVP4-9, PI = 9.8), were examined in vivo and in vitro. At 45 min after an i.v. administration to mice, the cerebrum-to-plasma concentration ratios of 35S-labeled AVP4-9 and 1251-labeled C-AVP4-9 were 0.103 and 0.330 ml/g cerebrum, respectively, and the BBB permeation clearances were 1.47 x 10-4 and 3.10 x 10-4 ml/min/g cerebrum, respectively. In the in vitro study using mouse brain capillary endothelial cells immortalized by SV40 infection (MBEC4), the acid- resistant binding values of 35S-labeled AMP4-9 and 125l-labeled C- AVP4-9 to MBEC4 at 120 min were 0.93 and 1.95 μl/mg protein (as the cell/medium ratios), respectively. 35S-labeled AVP4-9 showed two-phase saturable acid-resistant binding, and its half-saturation constants (K(D)) were 3.8 nM (high affinity) and 45.7 μM (low affinity). 125l-labeled C- AVP4-9 showed single-phase saturable acid-resistant binding, with a K(D) value of 16.4 μM. The acid-resistant binding of 125l-labeled C-AVP4-9 was significantly dependent on temperature and medium osmolarity. The acid- resistant binding of 1251-labeled C-AVP4-9 was inhibited by dancylcadaverine, phenylarsine oxide (endocytosis inhibitors), 2,4- dinitrophenol (a metabolic inhibitor), and AVP4-9, poly(L-lysine), and protamine (cationic substances), but not by poly(L-glutamic acid) (an anionic peptide) and the V1 and V2 vasopressin receptor antagonists. In addition, the conversion of C-AVP4-9 to AVP4-9 in the cerebral homogenate was confirmed by HPLC and mass spectrometry. The present results demonstrate that C-AVP4-9 is transported through the BBB more effectively than AVP4-9, via absorptive-mediated endocytosis, and that C-AVP4-9 is converted to the neuroactive parent peptide, AVP4-9, in the cerebrum.",
author = "Shuichi Tanabe and Yasuyuki Shimohigashi and Yasuhisa Nakayama and Takashi Makino and Tsugumi Fujita and Takeru Nose and Gozoh Tsujimoto and Teruo Yokokura and Mikihiko Naito and Takashi Tsuruo and Tetsuya Terasaki",
year = "1999",
month = "8",
day = "1",
language = "English",
volume = "290",
pages = "561--568",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog

AU - Tanabe, Shuichi

AU - Shimohigashi, Yasuyuki

AU - Nakayama, Yasuhisa

AU - Makino, Takashi

AU - Fujita, Tsugumi

AU - Nose, Takeru

AU - Tsujimoto, Gozoh

AU - Yokokura, Teruo

AU - Naito, Mikihiko

AU - Tsuruo, Takashi

AU - Terasaki, Tetsuya

PY - 1999/8/1

Y1 - 1999/8/1

N2 - The blood-brain barrier (BBB) transport and metabolism of a novel arginine-vasopressin fragment 4-9 [AVP4-9, isoelectric point; (pl) = 9.2] analog, that is, cationic AVP4-9 (C-AVP4-9, PI = 9.8), were examined in vivo and in vitro. At 45 min after an i.v. administration to mice, the cerebrum-to-plasma concentration ratios of 35S-labeled AVP4-9 and 1251-labeled C-AVP4-9 were 0.103 and 0.330 ml/g cerebrum, respectively, and the BBB permeation clearances were 1.47 x 10-4 and 3.10 x 10-4 ml/min/g cerebrum, respectively. In the in vitro study using mouse brain capillary endothelial cells immortalized by SV40 infection (MBEC4), the acid- resistant binding values of 35S-labeled AMP4-9 and 125l-labeled C- AVP4-9 to MBEC4 at 120 min were 0.93 and 1.95 μl/mg protein (as the cell/medium ratios), respectively. 35S-labeled AVP4-9 showed two-phase saturable acid-resistant binding, and its half-saturation constants (K(D)) were 3.8 nM (high affinity) and 45.7 μM (low affinity). 125l-labeled C- AVP4-9 showed single-phase saturable acid-resistant binding, with a K(D) value of 16.4 μM. The acid-resistant binding of 125l-labeled C-AVP4-9 was significantly dependent on temperature and medium osmolarity. The acid- resistant binding of 1251-labeled C-AVP4-9 was inhibited by dancylcadaverine, phenylarsine oxide (endocytosis inhibitors), 2,4- dinitrophenol (a metabolic inhibitor), and AVP4-9, poly(L-lysine), and protamine (cationic substances), but not by poly(L-glutamic acid) (an anionic peptide) and the V1 and V2 vasopressin receptor antagonists. In addition, the conversion of C-AVP4-9 to AVP4-9 in the cerebral homogenate was confirmed by HPLC and mass spectrometry. The present results demonstrate that C-AVP4-9 is transported through the BBB more effectively than AVP4-9, via absorptive-mediated endocytosis, and that C-AVP4-9 is converted to the neuroactive parent peptide, AVP4-9, in the cerebrum.

AB - The blood-brain barrier (BBB) transport and metabolism of a novel arginine-vasopressin fragment 4-9 [AVP4-9, isoelectric point; (pl) = 9.2] analog, that is, cationic AVP4-9 (C-AVP4-9, PI = 9.8), were examined in vivo and in vitro. At 45 min after an i.v. administration to mice, the cerebrum-to-plasma concentration ratios of 35S-labeled AVP4-9 and 1251-labeled C-AVP4-9 were 0.103 and 0.330 ml/g cerebrum, respectively, and the BBB permeation clearances were 1.47 x 10-4 and 3.10 x 10-4 ml/min/g cerebrum, respectively. In the in vitro study using mouse brain capillary endothelial cells immortalized by SV40 infection (MBEC4), the acid- resistant binding values of 35S-labeled AMP4-9 and 125l-labeled C- AVP4-9 to MBEC4 at 120 min were 0.93 and 1.95 μl/mg protein (as the cell/medium ratios), respectively. 35S-labeled AVP4-9 showed two-phase saturable acid-resistant binding, and its half-saturation constants (K(D)) were 3.8 nM (high affinity) and 45.7 μM (low affinity). 125l-labeled C- AVP4-9 showed single-phase saturable acid-resistant binding, with a K(D) value of 16.4 μM. The acid-resistant binding of 125l-labeled C-AVP4-9 was significantly dependent on temperature and medium osmolarity. The acid- resistant binding of 1251-labeled C-AVP4-9 was inhibited by dancylcadaverine, phenylarsine oxide (endocytosis inhibitors), 2,4- dinitrophenol (a metabolic inhibitor), and AVP4-9, poly(L-lysine), and protamine (cationic substances), but not by poly(L-glutamic acid) (an anionic peptide) and the V1 and V2 vasopressin receptor antagonists. In addition, the conversion of C-AVP4-9 to AVP4-9 in the cerebral homogenate was confirmed by HPLC and mass spectrometry. The present results demonstrate that C-AVP4-9 is transported through the BBB more effectively than AVP4-9, via absorptive-mediated endocytosis, and that C-AVP4-9 is converted to the neuroactive parent peptide, AVP4-9, in the cerebrum.

UR - http://www.scopus.com/inward/record.url?scp=0032780901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032780901&partnerID=8YFLogxK

M3 - Article

VL - 290

SP - 561

EP - 568

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -